For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
ProKidney Corp (NASDAQ: PROK) closed the day trading at $0.64 up 10.11% from the previous closing price of $0.58. In other words, the price has increased by $10.11 from its previous closing price. On the day, 1.54 million shares were traded. PROK stock price reached its highest trading level at $0.7308 during the session, while it also had its lowest trading level at $0.5919.
Ratios:
For a better understanding of PROK, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.96 and its Current Ratio is at 10.96.
On September 10, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $6.Guggenheim initiated its Buy rating on September 10, 2024, with a $6 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 22 ’25 when Control Empresarial de Capital bought 387,393 shares for $0.71 per share. The transaction valued at 276,366 led to the insider holds 73,842,723 shares of the business.
Control Empresarial de Capital bought 25,000 shares of PROK for $18,690 on Apr 17 ’25. The Add’l Rep. Persons-see Ex.99-1 now owns 73,455,330 shares after completing the transaction at $0.75 per share. On Apr 16 ’25, another insider, Control Empresarial de Capital, who serves as the Add’l Rep. Persons-see Ex.99-1 of the company, bought 100,000 shares for $0.75 each. As a result, the insider paid 74,820 and bolstered with 73,430,330 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PROK now has a Market Capitalization of 1811827200 and an Enterprise Value of 1120099328. For the stock, the TTM Price-to-Sale (P/S) ratio is 601.65. Its current Enterprise Value per Revenue stands at 3660.455 whereas that against EBITDA is -6.447.
Stock Price History:
The Beta on a monthly basis for PROK is 1.37, which has changed by -0.7117647 over the last 52 weeks, in comparison to a change of 0.12677538 over the same period for the S&P500. Over the past 52 weeks, PROK has reached a high of $2.59, while it has fallen to a 52-week low of $0.46. The 50-Day Moving Average of the stock is -19.39%, while the 200-Day Moving Average is calculated to be -53.32%.
Shares Statistics:
Over the past 3-months, PROK traded about 1.17M shares per day on average, while over the past 10 days, PROK traded about 2663010 shares per day. A total of 129.54M shares are outstanding, with a floating share count of 94.19M. Insiders hold about 27.29% of the company’s shares, while institutions hold 41.58% stake in the company. Shares short for PROK as of 1749772800 were 16799156 with a Short Ratio of 14.34, compared to 1747267200 on 15942724. Therefore, it implies a Short% of Shares Outstanding of 16799156 and a Short% of Float of 18.490000000000002.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of ProKidney Corp (PROK) reflects the combined expertise of 4.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.1 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$0.45 and -$0.68 for the fiscal current year, implying an average EPS of -$0.56. EPS for the following year is -$0.57, with 5.0 analysts recommending between -$0.4 and -$0.79.
